This site is an archive for Genesis Research and Development Corporation Limited, a New Zealand based Biotech Company that was listed on NZSX and ASX from September 2000 to August 2013 with the ticker GEN.



From 1994 to 2010, Genesis operated as a biotechnology company based in Auckland, New Zealand, developing therapeutics for the treatment of cancer and diseases of the immune system and agricultural biotech projects.

Genesis established Solirna Biosciences Ltd to develop a novel single stranded gene silencing technology which acts through the RNAi mechanism.

In 2010 Genesis and Solirna ceased operations due to lack of funding.